Novaflux Inc.

Princeton, NJ

UEI
EB2BHWSBLZT3
CAGE
7YHD6
Primary NAICS
541990 All Other Professional, Scientific, and Technical Services
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2 Emmons Dr, Princeton, NJ 08540, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Similar vendors

About the company

Novaflux Inc. is a for-profit corporate entity registered to receive federal awards from the U.S. government. It develops innovative technologies in areas such as healthcare and medical devices.

Novaflux Inc. has received several federal grants from agencies like the National Institutes of Health (NIH) and its institutes, including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). One major project involved developing a novel hand hygiene product using microstructured fluids to remove Clostridioides difficile spores, which cause healthcare-associated infections. This $2.9 million NIAID grant aimed to optimize the formulation, manufacture the product under GMP, and test its safety and tolerability. Another NIDDK grant for nearly $1 million supported developing an innovative dialyzer with long filter life and reduced need for anticoagulation therapies. Additionally, Novaflux received a $300,000 NIAID grant to optimize sampling methods for culturing duodenoscopes using portable two-phase flow technology to prevent infections.

SBA capabilities narrative

Research and Development of Medical Devices

Quick answers

Is Novaflux Inc. registered in SAM.gov?

Yes. Novaflux Inc.'s SAM.gov registration is active through June 12, 2027.

What is Novaflux Inc.'s most recent federal award?

Novaflux Inc.'s most recent federal grant award is Novel hand hygiene product to remove clostridioides difficile spores - 7. Project summary/abstract c. Difficile now… (R44AI170313), from National Institute of Allergy and Infectious Diseases (NIH), on March 9, 2023.

On GovTribe

See Novaflux Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors